AC Immune SA (ACIU)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about AC Immune SA (ACIU)
Go deeper and ask any question about ACIU
Company Performance
Current Price
as of Sep 13, 2024$3.18
P/E Ratio
N/A
Market Cap
$316.98M
Description
AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.
Metrics
Overview
- HQLausanne, VD
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerACIU
- Price$3.18+4.26%
Trading Information
- Market Cap$316.98M
- Float61.96%
- Average Daily Volume (1m)83,339
- Average Daily Volume (3m)168,710
- EPS-$0.72
Company
- Revenue$17.44M
- Rev Growth (1yr)N/A
- Net Income-$25.16M
- Gross MarginN/A
- EBITDA Margin-2,977.29%
- EBITDA-$22.61M
- EV$205.91M
- EV/Revenue11.81
- P/EN/A
- P/S18.15